B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $37 to $45.
B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $37 to $45.